SHANGHAI AOHUA PHOTOELECTRICITY ENDOSCOPE CO.(688212) 山西证券·2025-04-23 00:25Investment Rating - The report maintains an "Increase-B" rating for the company [1][10] Core Views - The company's domestic business growth is limited due to a decrease in bidding activities, while overseas business is progressing rapidly [1][6] - In 2024, the company achieved a revenue of 750 million yuan, a year-on-year increase of 10.54%, but the net profit decreased by 63.68% to 21.01 million yuan [5][10] - The company is focusing on expanding its overseas marketing network, which has led to significant growth in international sales [6][10] Financial Performance Summary - For 2024, domestic revenue was 586 million yuan (up 3.93% YoY) and international revenue was 161 million yuan (up 42.70% YoY) [6][10] - In Q1 2025, the company reported a revenue of 124 million yuan, a decrease of 26.92% YoY, with a net loss of 28.79 million yuan [5][10] - The gross margin and net margin both declined in 2024, with gross margin at 68.12% and net margin at 2.71% [7][10] Research and Development - The company increased R&D expenditure to 163.6 million yuan in 2024, accounting for 21.83% of revenue, with significant advancements in product lines [8][10] - New product launches include electronic bladder and ureteroscopes, and a high-spectral platform for enhanced medical imaging [8][9] Future Projections - Revenue projections for 2025-2027 are 873 million, 1.071 billion, and 1.272 billion yuan, representing growth rates of 16.4%, 22.7%, and 18.8% respectively [10][12] - Expected net profits for the same period are 75 million, 124 million, and 172 million yuan, with corresponding EPS of 0.56, 0.92, and 1.28 yuan [10][12]